ArriVent BioPharma (AVBP) Competitors $17.26 -0.75 (-4.14%) As of 10:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. RXRX, TWST, BHC, NAMS, HCM, MLTX, IBRX, BEAM, VCEL, and MIRMShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Bausch Health Companies (BHC), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), MoonLake Immunotherapeutics (MLTX), ImmunityBio (IBRX), Beam Therapeutics (BEAM), Vericel (VCEL), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Recursion Pharmaceuticals Twist Bioscience Bausch Health Companies NewAmsterdam Pharma HUTCHMED MoonLake Immunotherapeutics ImmunityBio Beam Therapeutics Vericel Mirum Pharmaceuticals ArriVent BioPharma (NASDAQ:AVBP) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership. Do analysts rate AVBP or RXRX? ArriVent BioPharma presently has a consensus target price of $39.00, suggesting a potential upside of 121.39%. Recursion Pharmaceuticals has a consensus target price of $8.25, suggesting a potential upside of 64.47%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe ArriVent BioPharma is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Recursion Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has preferable earnings and valuation, AVBP or RXRX? ArriVent BioPharma has higher earnings, but lower revenue than Recursion Pharmaceuticals. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$2.57-6.85Recursion Pharmaceuticals$58.49M34.48-$328.07M-$1.66-3.02 Which has more volatility and risk, AVBP or RXRX? ArriVent BioPharma has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Recursion Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Does the MarketBeat Community favor AVBP or RXRX? Recursion Pharmaceuticals received 9 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 55.56% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes21100.00% Underperform VotesNo VotesRecursion PharmaceuticalsOutperform Votes3055.56% Underperform Votes2444.44% Do insiders and institutionals hold more shares of AVBP or RXRX? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is AVBP or RXRX more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. ArriVent BioPharma's return on equity of -43.89% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Recursion Pharmaceuticals -579.52%-76.56%-55.68% Does the media prefer AVBP or RXRX? In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.20 beat Recursion Pharmaceuticals' score of 0.79 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive SummaryArriVent BioPharma beats Recursion Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Remove Ads Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$594.43M$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-6.807.1123.1018.82Price / SalesN/A207.54366.7488.84Price / CashN/A65.6738.1634.64Price / Book-3.686.146.684.18Net Income-$69.33M$142.11M$3.20B$247.10M7 Day Performance-5.14%-6.00%-3.97%-2.75%1 Month Performance-20.04%-6.97%1.65%-3.92%1 Year Performance-2.78%-12.14%8.26%-0.12% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma1.3434 of 5 stars$17.25-4.1%$39.00+126.0%+0.0%$587.32MN/A-6.7240RXRXRecursion Pharmaceuticals2.3704 of 5 stars$6.79+1.6%$8.25+21.5%-39.7%$2.73B$58.49M-4.44400TWSTTwist Bioscience4.0541 of 5 stars$44.94+4.8%$54.40+21.1%+16.1%$2.68B$330.19M-13.30990Positive NewsBHCBausch Health Companies4.0163 of 5 stars$7.27+1.5%$7.42+2.1%-40.0%$2.67B$9.63B-60.5419,900News CoverageNAMSNewAmsterdam Pharma2.5952 of 5 stars$24.00+0.5%$43.33+80.6%-14.9%$2.64B$45.56M-9.234News CoverageHCMHUTCHMED1.7142 of 5 stars$15.09+0.7%$19.00+25.9%-4.9%$2.63B$630.20M0.001,988Positive NewsMLTXMoonLake Immunotherapeutics2.1503 of 5 stars$40.58+1.1%$80.50+98.4%-19.5%$2.60BN/A-31.462News CoverageIBRXImmunityBio2.0573 of 5 stars$2.85+5.2%$12.19+327.6%-42.1%$2.43B$14.75M-3.10590Analyst ForecastBEAMBeam Therapeutics3.234 of 5 stars$24.01+3.0%$50.82+111.7%-39.5%$2.40B$63.52M-13.64510Short Interest ↑Gap DownVCELVericel3.3372 of 5 stars$47.94+3.6%$62.29+29.9%-13.6%$2.40B$237.22M799.13300Positive NewsMIRMMirum Pharmaceuticals4.4016 of 5 stars$47.02flat$58.20+23.8%+78.5%$2.30B$336.89M-23.28140Positive News Remove Ads Related Companies and Tools Related Companies Recursion Pharmaceuticals Competitors Twist Bioscience Competitors Bausch Health Companies Competitors NewAmsterdam Pharma Competitors HUTCHMED Competitors MoonLake Immunotherapeutics Competitors ImmunityBio Competitors Beam Therapeutics Competitors Vericel Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
